About Mazdutide
Mazdutide is studied as a dual GLP-1 receptor and glucagon receptor agonist in metabolic research. Supplied as a lyophilized powder for laboratory investigations into incretin/glucagon pathway signaling, energy balance mechanisms, and glucose regulation in controlled experimental settings. Each batch undergoes analytical verification for identity and purity using HPLC and mass spectrometry. Supplied as: Lyophilized powder Purity: >95-99 (HPLC verified) Storage: Store desiccated at ?20�C for long-term. Short-term room temperature exposure (around 1 month) during shipping/handling is generally acceptable if kept sealed, dry, and protected from heat/light. Designation: FOR RESEARCH USE ONLY. Not intended for human or animal consumption.
Latest Research
Patent landscape and therapeutic evolution of mazdutide: a dual GLP-1/Glucagon receptor agonist for obesity and type 2 diabetes.
Recent research on Mazdutide: Patent landscape and therapeutic evolution of mazdutide: a dual GLP-1/Glucagon receptor agonist for obesity and type 2 diabetes.
Read Full Study on PubMedMazdutide 9 mg in Chinese adults with a body mass index ≥30 kg/m(2) but without diabetes: A phase 2 randomized controlled trial.
Recent research on Mazdutide: Mazdutide 9 mg in Chinese adults with a body mass index ≥30 kg/m(2) but without diabetes: A phase 2 randomized controlled trial.
Read Full Study on PubMedAdditional Studies
Efficacy and Safety of Mazdutide in Managing Overweight and Obesity Among Non-Diabetic Adults: A Meta-Analysis of Randomised Controlled Trials.
Recent research on Mazdutide: Efficacy and Safety of Mazdutide in Managing Overweight and Obesity Among Non-Diabetic Adults: A Meta-Analysis of Randomised Controlled Trials.
Read on PubMedMazdutide Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease by Modulating Endoplasmic Reticulum Stress, Improving Lipid Metabolism and Alleviating Inflammation.
Recent research on Mazdutide: Mazdutide Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease by Modulating Endoplasmic Reticulum Stress, Improving Lipid Metabolism and Alleviating Inflammation.
Read on PubMedIncretin-Based Dual and Triple Agonists in Overweight or Obese Individuals: A Systematic Review and Meta-Analysis.
Recent research on Mazdutide: Incretin-Based Dual and Triple Agonists in Overweight or Obese Individuals: A Systematic Review and Meta-Analysis.
Read on PubMedObesity in China: current progress and future prospects.
Recent research on Mazdutide: Obesity in China: current progress and future prospects.
Read on PubMedA Clinical Comprehensive Evaluation of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes Management.
Recent research on Mazdutide: A Clinical Comprehensive Evaluation of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes Management.
Read on PubMedMazdutide versus Semaglutide for the treatment of type 2 diabetes and obesity: Rationale, design and baseline data of DREAMS-3 phase 3 trial.
Recent research on Mazdutide: Mazdutide versus Semaglutide for the treatment of type 2 diabetes and obesity: Rationale, design and baseline data of DREAMS-3 phase 3 trial.
Read on PubMedRelated Research
Purchase Mazdutide from Verified Peptides
High-purity research peptides with full analytical verification
- 99% Purity (HPLC Verified)
- Full Certificate of Analysis
- Same Day Dispatch
- Free UK Shipping Over £75
Research Disclaimer
The research articles and studies referenced on this page are for informational purposes only. All products are sold for research use only and are not intended for human or animal consumption. The information provided does not constitute medical advice, diagnosis, or treatment. Always consult with qualified healthcare professionals before making any decisions related to health or medical treatment.